Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Four Partnerships, Boosts ‘Revenue Picture’

  • Lexaria Bioscience, a global innovator in drug delivery platforms, recently announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S
  • According to coverage by Zacks Small-Cap Research, who value Lexaria at $15 per share, the most impactful of these partnerships is with Premier because the company is expected to start paying license fees in early September
  • In a June 7 Fireside Chat, Lexaria Chair and CEO Chris Bunka disclosed that the company is capitalizing on partnerships with “national players in different areas of the world” to improve its “revenue picture” and offset its cash burn
  • In the longer term, the company is targeting milestone payments from large national and international consumer companies and pharmaceutical organizations

In a June 7 Fireside Chat hosted by John D. Vandermosten, CFA, of Zacks Small-Cap Research (“SCR”), Lexaria Bioscience (NASDAQ: LEXX) Chair and CEO Chris Bunka expressed hope that the then-ongoing negotiations with “national players in different areas of the world” would yield contracts that would significantly improve its revenue (https://ibn.fm/qhlo1). The negotiations led to separate announcements that form the basis of Zacks SCR’s latest coverage of the company, who value Lexaria at $15 per share (https://ibn.fm/OvOaJ).

“Lexaria experienced a substantial amount of activity on both the drug development front and in closing agreements with partners since the end of the fiscal second quarter,” Zacks notes in its coverage (https://ibn.fm/sGXzP). “The company announced four material partnerships in June that will provide a variety of upfront, milestone, and royalty opportunities over the next quarters and years to come.”

Lexaria announced partnerships with Premier Wellness Science Co., BevNology, AnodGen Bioceuticals, and Valcon Medical A/S. The most impactful of these, the Zacks report notes, is with Premier because the company is expected to start paying license fees and launch its products using Lexaria’s patented DehydraTECH(TM) technology in Japan. The agreements with AnodGen and Valcon, on the other hand, are longer-term in nature.

As detailed in a June 3 press release, Lexaria granted an exclusive license to Premier authorizing the latter’s use of its DehydraTECH technology in various cannabidiol (“CBD”) products that may be in oral liquid or non-liquid form. In addition, per the terms of the agreement, DehydraTECH may also be used in topical, hair-care, lip-care, and cosmetics segments (https://ibn.fm/3cnkt).

“The arrangement includes minimum payments of $4.5 million to be paid over the first five years of the deal to maintain exclusivity,” Zacks SCR explains. “The license payments will start from a small base and grow as the arrangement moves into its final years. First payments will be made to Lexaria on September 1. Royalty percentages were not disclosed, nor were Premier sales forecasts; however, the press release noted that under the worst-case sales projection by Premier, Lexaria could receive annual royalties of over $5 million.”

The license and royalty payments are part of a short-to-medium-term revenue-generation strategy, with the company eventually targeting milestone payments from companies primarily in the pharmaceutical sector as part of its longer-term strategy. And to make its DehydraTECH technology more attractive for large national and international consumer companies and pharmaceutical organizations, Lexaria has invested a lot of time and resources in validating its R&D programs (https://ibn.fm/ZulHA).

“If people are unaware, for small pharma companies like ourselves, our most likely path to commercial success comes through milestone payments with pharma where you elevate, through Phase I, into Phase II, and so on, a drug or delivery system. And usually, those payments are quite large, usually, tens of millions and sometimes hundreds of millions of dollars, [and can cover our R&D programs]. And I want to assure our shareholders that we want to be able to cover these programs without issuing any more equity,” Chris Bunka said during the Fireside Chat.

In the interim, Lexaria has maintained tremendous fiscal prudency while supporting its R&D programs. According to Bunka, the company’s spending is within its projected budgetary expectations, having raised $15 million in 2021. Currently, the company has between $7-8 million in its bank accounts, which it projects will support its operations through the third quarter of 2023. But by partnering with the companies such as Premier, Lexaria is making strides to improve its “revenue picture” and offset “more of our cash burn.”

Lexaria is a global innovator in drug delivery platforms that has developed DehydraTECH, shown to improve the bioavailability, speed of onset, and brain absorption of pharmaceuticals and therapeutics.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW – Report Says Senate Intelligence Committee Chair Toned Down Cannabis Amendment to Ease Bill Passage

Cannabis reform is still quite controversial. Reform activists have had a hard time getting reform past lawmakers who oppose cannabis for a variety of reasons. In many cases, they have been forced to give up certain provisions in their cannabis initiatives to make them more palatable to Republican and Democratic lawmakers who were withholding their support. A recent report from the Senate Intelligence Committee has revealed that the panel did just that last month.

In late June, the Senate committee voted in favor of a measure that would make it possible for people who had used cannabis in the past to work for intelligence agencies such as the Central Intelligence Agency (CIA) and the National Security Agency (NSA). The measure was then attached to the Intelligence Authorization Act, which was slated to go through both chambers before reaching the president’s desk. However, the report says that the committee adopted a scaled-back version of the original proposal instead.

The original version, which would have provided cannabis users with even more protections, was dialed down to make it more attractive and increase its chances of passing. In fact, the vote tally reveals that the scaled-back version of the proposal even drew the support of notorious antilegalization lawmaker Senator Tom Cotton. The proposal was first introduced by Senator Ron Wyden and attached to the Intelligence Authorization Act as an amendment.

The report notes that the proposal would have barred any federal agency from limiting their employees’ access to classified information due to past or current marijuana use. However, a scaled-back, second-degree amendment from Chairman Mark Warner and Senator Michael Bennet toned down Wyden’s original proposal and limited cannabis protections to individuals working for federal intelligence agencies.

Furthermore, the scaled-down amendment changed the language from “past or present” marijuana use to “pre-employment” marijuana consumption. According to a spokesperson from Warner’s office, Warner offered the revised proposal after the first version of the amendment failed to garner enough votes. Ultimately, the revised amendment passed in an 11 to 5 vote that saw notable members of the senate such as Senators Cotton, Diane Feinstein and Susan Collins — all of whom have a long history of opposing cannabis reform — supporting the legislation.

However, this vote may be indicative of a shift in perspective for the two latter senators, especially in regard to modest cannabis reform. Collins has previously supported proposals on access to cannabis by veterans and cannabis banking reform while Feinstein is a proponent of cannabis research.

While the cannabis industry and its actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) would have preferred to see sweeping marijuana reforms at the federal level, the incremental approach now seems the more realistic way, and advocates need to exercise patience as the process plays out over time.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NIH Seeks Input on Cannabis Research Barriers

In a request for information published last week, the National Institutes on Health (NIH) indicated that marijuana has been used for thousands of years for therapeutic purposes despite the lack of sufficient data supporting such medicinal use. The agency is now looking to identify the barriers that have been making it hard for the scientific community to study this plant and its constituents.

In that notice, the top federal agency revealed that eight agencies under its umbrella are partnering in this effort to collect information spelling out why conducting cannabis research is difficult. The barriers could include the current federal classification of the substance as a Schedule 1 drug.

The NIH goes on to say that despite the fact that the U.S. Food & Drug Administration has approved therapies that are based on cannabinoids, there is no scientific basis to support some of the medical uses for which cannabis has been legalized at state level. For that reason, the agency wants to know the barriers in the way of conducting research to ascertain the specific benefits or potential risks associated with using marijuana to manage different health conditions. Such needed research would provide scientific proof of the efficacy or otherwise of marijuana for different clinical indications so that policymakers and the general population can make informed decisions.

The notice spells out some of the barriers hindering marijuana research. These include unanticipated costs incurred during the process of obtaining a license to conduct a study on marijuana, lack of an appropriate quantity and quality of research-grade marijuana as well as a shortage of the right tools to measure different aspects of marijuana use.

The note mentioning the lack of suitable marijuana products for research may be an indirect reference to the fact that for several decades, only one government-owned facility in Mississippi was allowed to produce the marijuana used for research purposes. Numerous complaints have been voiced about the quality of this marijuana, with some saying it was closer to hemp than the marijuana people access in state-legal retail outlets. The Drug Enforcement Administration has since granted licenses to additional suppliers and manufacturers, and there is pressure to permit scientists to gain direct access to the marijuana products sold in retail outlets so that any research done reflects the realities of what people are using.

The RFI published says that the agency wants to gain a better understanding of those barriers and eventually come up with remedies to ease the work of studying marijuana. The NIH also outlined the specific aspects it was interested in obtaining input about. Those include the research gaps where data is needed, the desirable infrastructure to facilitate the needed research, how the NIH can help expand scientific research into cannabis and so on. The deadline for receiving the input is Oct. 15, 2022.

Hopefully, the information gathered will result in the implementation of much-needed reforms so that industry actors such as Prime Harvest Inc. can avoid jumping through endless hoops whenever they want to conduct studies geared at furthering their corporate goals.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – LFTD Partners Inc. (LIFD) Releases Q2 2022 Financial Report

LFTD Partners (OTCQB: LIFD), the corporate parent of leading cannabis and psychedelics manufacturer Lifted Made, is reporting on its second quarter 2022, which is the period ended June 30, 2022. Highlights of the report include revenue for the quarter totaling $16,776,502, a 151% increase from the $6,695,144 reported in Q2 2021, and an increase in operating margin of 3.14%, with Q2 2022 coming in at 26.40%. GAAP net income from the quarter increased — the eighth consecutive quarter of upward movement — totaling $3,219,460 up from $1,596,154 the same period last year. The company reported a 64% increase in basic earnings per share (“EPS”), which went up from $.14 in second quarter 2021 to $0.23 per share Q2 2022; diluted EPS was also up, showing an 82% increase from $0.11 to $0.20 per share. The company noted that basic and diluted weighted average shares outstanding for the three months were 14,099,007 and 15,906,205, respectively. LFTD reported more than $3.751 million cash on hand at the end of the quarter, with an increased inventory of $10,049,245, up from $3,809,944. The company’s current assets totaled $19,678,947, a 50% increase over the same period last year, with working capital going up 725%, totaling $10,284,320, up from $1,246,426. “Q2 2022 was a record quarter for us in terms of net income, earnings per share and free cash flow,” said LFTD Partners COO and vice chair and Lifted Made founder and CEO Nicholas S. Warrender in the press release.

To view the full press release, visit https://cnw.fm/Tq18F

About LFTD Partners Inc.

LFTD Partners is focused on acquiring rapidly growing and profitable companies that sell branded hemp-derived cannabinoid products, emerging psychedelic products and other alternative lifestyle products. LFTD Partners’ first wholly owned subsidiary is Lifted Made, which sells award-winning, hemp-derived cannabinoid products and other psychedelic and alternative lifestyle products under its flagship brands Urb Finest Flowers and Silly Shruum. LFTD Partners also owns percentages of CBD-infused beverage and products maker Ablis and distillers Bendistillery Inc. (d/b/a Crater Lake Spirits) and Bend Spirits Inc., all located in Bend, Oregon. For more information about the company, please visit www.LFTDPartners.com and www.LiftedMade.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Feds Seek Vendor to Test for Cannabis Compounds in Users’ Breath

As more states legalize medical and recreational cannabis use, law enforcement and opponents of cannabis reform argue that marijuana legalization will lead to increased rates of cannabis-impaired driving and traffic incidents. But while police officers can easily test for alcohol impairment using breathalyzer tests, there are currently no standardized tests to check for THC impairment via the breath.

Furthermore, research has uncovered that THC blood levels are not a reliable indicator of intoxication and impairment levels. Studies have found that the base THC blood level of long-term cannabis users can be higher than the legal limit set in several states. THC can also remain in the blood for hours after consumption and indicate impairment long after its effects have faded.

As such, authorities have been interested in developing technology that would allow police officers to accurately test for THC impairment onsite. The federal government plans on investing more than $1.4 million in studies designed to determine how the concentration of cannabis compounds changes in people’s breath over time after they consume cannabis.

The National Institute of Standards and Technology (NIST) recently posted a “sources sought,” stating that it is searching for a vendor that is able to help run a study that would collect blood and breath samples and then test those samples for evidence of acute cannabis use by checking for cannabinoids such as delta-9 THC and their metabolites.

NIST acting director of media relations Richard Press says that the nonregulatory agency is looking for a contractor that will recruit study participants, collect breath samples after the participants consume their own state-legal marijuana and then send the samples to NIST laboratories for analysis. He said that the purpose of the sources sought notice was to notify potential contractors of the study requirements.

Over the past decade, researchers have tried to develop machinery that would allow them to test for THC impairment the way breathalyzers test for alcohol. However, the industry hasn’t been able to develop an efficient standard testing method for cannabis impairment. With dozens of states now allowing cannabis consumption, the need for a standard device that can test for cannabis impairment has grown.

Titled Breath Measurements of Acute Cannabis Elimination (BACE), the upcoming study will research how the cannabinoid concentration in a person’s breath changes hours after they consume cannabis, Press says. The study’s objective will be to determine whether or not THC can remain in cannabis users’ breath even after they abstain for long periods.

The entire cannabis industry, including entities such as Flora Growth Corp. (NASDAQ: FLGC), would support a reliable way to detect impaired drivers, so the effort by NIST to study this matter is a welcome one.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Illinois Legislator to File Bill Centralizing Marijuana Regulation

Many people say the legal marijuana industry in Illinois has complex regulations and that there is room for politics to interfere with the process of licensing businesses. The possibility of litigation against the licensing system is also high, and some are calling for the establishment of a commission to streamline the regulatory process.

One of the people thinking this way is Rep. Marcus Evans, a Democratic lawmaker from Chicago. He revealed that he is planning to table a bill that will create a cannabis commission similar to the commissions governing the gaming and alcohol industries. Evans is irked by the numerous state agencies that applicants have to reach out to in their bid to obtain a license. Each step of this lengthy process involves the payment of fees, and these can quickly add up. He says matters are worse for social equity applicants who have even more steps to follow before they get the nod to participate in the legal marijuana industry in the state.

Evans also says creating a cannabis commission will save time and reduce the confusion surrounding the myriad state agencies with which applicants have to engage. He says he requires the help of a flow chart when explaining to people the process of getting a business licensed.

Pam Althoff, executive director of the Cannabis Association of Illinois, agrees. She wants to see the regulatory process streamlined so that people don’t have to contact different agencies, each of which plays a minor role in the licensing process. Some of the departments that applicants have to interface with include public health, revenue, agriculture, police and others.

Evans’ plan is to table a bill that will see the creation of a commission having seven individuals, including an executive director who will be a full-time employee. Other members would be representatives selected by the leaders of the state assembly along with gubernatorial appointees. The lawmaker believes that such a commission will bring stability to the work of regulating the marijuana industry and that future political interference in the licensing process will be forestalled, especially when new leaders who aren’t keen on a legal marijuana industry take office.

Cannabis sales are booming in the state, with records showing that a hefty $1.5 billion was generated as total sales during the 2021–2022 fiscal year. From this amount, $445 million went to the state coffers in the form of taxes and fees. These tax dollars are distributed according to a predetermined formula. For example, 25% goes to grants issued to organizations working in the communities that bore the brunt of the drug war while 8% is earmarked for supporting law enforcement efforts in the state.

It is such a progressive approach to overseeing the marijuana industry that will create enabling conditions for multistate cannabis operators such as American Cannabis Partners to thrive in the different markets that they set up shop in.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The New York Cannabis and Hemp Convention to Boost the Growing Local Markets

Businesses, entrepreneurs, advocates, patients, investors, educators, and consumers, are invited to attend the NECANN Convention, a physical event being held in Albany, New York on August 26-27, 2022. 

NECANN has been producing popular and influential events to local communities throughout the northeast and beyond since 2014, shaping the developing cannabis economy by creating an important hub of resources and communication focused on local markets. NECANN events attract a huge number of hemp, MMJ, and cannabis industry professionals in the Northeast, and represent a home base for the New England cannabis industry.

The New England Cannabis Convention offers a wonderful opportunity for the local community to grow and prosper. There are robust networking, communication, and business opportunities for cannabis cultivators, consumers, and business vendors across the region. The convention brings together the local cannabis community and fosters interactive trade and communication. New and established businesses, cannabis growers, and dealers, can discover business prospects and connect with top cannabis companies and investors. For budding entrepreneurs, it’s a wonderful forum that offers the opportunity to learn the latest industry trends in cannabis cultivation and trading.

Touted as the key event for cannabis businesses on the East Coast, NECANN events are considered one of the best organized for the cannabis community, professionally run by a highly experienced team that devotes months of planning and research to put the event together. While these events offer phenomenal networking and informational opportunities, participants also enjoy numerous amenities in a fun environment. 

Cannabis experts throughout the region will share insights and their knowledge with a wide cannabis audience through vending, guest speaking, and interactive sessions at NECANN New York. The event is attended by industry stalwarts and thought leaders who will discuss business strategies and the future trends of this growing industry. They will also throw light on the latest products and technologies specifically oriented to the local cannabis community. Businesses looking to pitch their products and services should make contact as soon as possible through the link below.

To learn more, please visit https://necann.com/new-york-convention/.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study

  • Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension
  • HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021
  • It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension
  • Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of this compound that might otherwise remain undetected

In November 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most ambitious hypertension study yet, HYPER-H21-4. The goal of the study, according to Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka, was to “Support the company’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” (https://cnw.fm/8fXrT). 

At the close of the year, Lexaria received independent Review Board (“IRB”) approval ahead of schedule, which marked a significant milestone for the company. It would set the stage for the commencement of the study in the year 2022 while allowing Lexaria to explore the full potential of its patented DehydraTECH(TM) technology in hypertension treatment (https://cnw.fm/Ozbsy).

On July 27, 2022, Lexaria announced that dosing with DehydraTECH-processed cannabidiol (“DehydraTECH-CBD”) had been completed in a multi-week human clinical hypertension study. Most notably, no serious adverse events were reported due to the dosing: the absence of serious adverse events is a critical goal of typical Phase I and Phase II FDA-registered studies Furthermore, the whole undertaking was completed on schedule, another huge milestone for the company as it works towards enhancing its understanding of DehydraTECH-CBD and its effectiveness in treating cardiovascular and other disease states beyond hypertension (https://cnw.fm/EWmEf). 

“We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” noted Mr. Bunka.

“Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorizations,” he added.

This HYPER-H21-4 study consisted of male and female volunteers aged between 40 and 70. These volunteers had documented or measured elevated blood pressure, mild (stage 1) hypertension, to moderate (stage 2) hypertension. They received DehydraTECH-CBD every day for five weeks, with the doses escalating between 225 mg/day to 450 mg/day over the study duration, adjusted relative to body weight.

The study’s extended duration allowed Lexaria to collect critical data monitoring the safety and efficacy of its DehydraTECH-CBD over time. This allowed the company to evaluate the potential for longer health benefits. Some of the study outcomes include vascular health, incorporating arterial stiffness and autonomic balance, electrocardiogram (“ECG”) analysis, brain structure and function through MRI testing, and blood biomarkers, among others. 

Lexaria is confident that each of these data sets will lead to additional applications for DehydraTECH-CBD while also providing valuable additional insights into the long-term health benefits of this compound that might otherwise remain undetected. Analysis of most of the data collected since the beginning of the study has begun and results should begin to be released in September 2022, with additional results to be release subsequently.

HYPER-H21-4 builds on HYPER-H21-1 and HYPER-H21-2 studies, all conducted in 2021. Both of these previous studies evidenced a rapid and sustained drop in blood pressure with DehydraTECH-CBD in what Mr. Bunka described as “encouraging early results.”  As a result, Lexaria is optimistic that with the success of its latest study, its DehydraTECH-CBD will offer a better alternative to existing hypertension drugs in the market, mostly known for their unwanted side effects once approved.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Why Marijuana Retailers Need to Look Beyond THC Concentration

Most cannabis buyers have only the THC concentration in mind when they are choosing a marijuana product, but hasn’t the time come for retailers to look beyond how much THC a given product contains while making a decision about its quality?

Until recently, marijuana was illegal, but dozens of U.S. states have since legalized it either for medical or recreational use. One strong reason for outlawing marijuana was its psychoactive compound THC, which is why most tests look for THC metabolites in the blood, urine and even hair samples.

It is therefore understandable that people will focus on potency (THC concentration) when choosing a product to buy. In the eyes of consumers, more THC equals a promise of a better experience. Or does it?

Buyers are beginning to appreciate that high THC concentrations aren’t for everyone. For example, newbies to smoking cannabis can be spooked when they consume marijuana with THC that is stronger than 25% since it may quickly trigger psychoactive effects. Additionally, some marijuana users prefer a chilled kind of high, and high THC numbers cannot give them what they seek.

The space is beginning to see a growing body of discerning cannabis users who look beyond THC concentration when evaluating the desirability of a given marijuana product. These buyers want to know the flavonoids, terpenes and minor cannabinoids (such as CBG and CBN) present in a product so that they can judge whether that product will give them the experience they are looking for.

This growing sophistication is what marijuana retailers should be working to capitalize on as the nascent industry matures. This is how brands can stand out instead of remaining stuck in the THC concentration battle with every player in the industry.

For starters, manufacturers need to improve their labels to reflect all the compounds present in a given product. Many states only require the amount of THC in a product to be indicated on the label, but future-minded companies can go beyond this basic requirement and outline all compounds available in the product. Remember, the entourage effect is pivotal to one’s experience, so the obsession with THC concentration misses a vital opportunity to stand out.

Budtenders are at the frontline when it comes to getting cannabis products to customers. These professionals need to be adequately trained so that they can educate customers about how, for example, a given terpene combination plus THC of a certain level would be best for meeting certain needs of buyers. Companies can nurture customer loyalty when they adopt this approach, and they can also cement their uniqueness in the industry.

The growing customer sophistication is also creating market for ancillary products such as the grow pods made by Advanced Container Technologies Inc. (OTC: ACTX). Before long, mass-produced cannabis products will be competing with homegrown ones as people opt to take matters into their own hands in jurisdictions where this is allowed.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Las Vegas Awaits Launch of Marijuana Consumption Lounges

Although they are a relatively new concept, marijuana consumption lounges are probably the most controversial aspect of the entire cannabis reform movement. The idea is to provide public rooms where customers can consume cannabis without running afoul of state cannabis laws. While more than a dozen states have now legalized recreational cannabis consumption, they have also outlawed public consumption and made it almost impossible for nonresidents to legally consume the cannabis they have purchased.

New York was among the first states to allow cannabis consumption sites for adults aged 21 and over. The state recently passed a bill that would allow licensed businesses to sell cannabis products and provide a space for customers to consume the cannabis they bought on site.

Just a few months later, Las Vegas is poised to launch its first marijuana consumption site as well, becoming the second state in the country to legalize the operation of consumption lounges. Regulators from Nevada recently finalized regulations for the state’s cannabis market that would lead to the opening of an estimated 60 to 65 marijuana consumption lounges. The move was aimed at making the state more attractive to tourists and boosting cannabis tourism, a segment that is now estimated to be worth $17 billion.

According to a public statement from the Cannabis Compliance Board, the first consumption sites are slated to open before the end of the year. The state of Nevada will issue some 40 to 45 licenses to existing cannabis stores as well as 20 licenses to independent consumption lounges. Another 10 licenses will be issued to social-equity applicants, people who live in disadvantaged areas, or people with prior nonviolent cannabis convictions.

The social equity licenses will have discounted fees. As per the finalized regulations, regulators will begin processing consumption lounge licenses starting this fall.

Nearly 65 applicants have already expressed interest in receiving the consumption lounge licenses, and they have even begun leveraging strategies to help the businesses stay profitable in the new cannabis-consumption-lounge segment.

This includes providing calm, comfortable spaces to act as an alternative to the Strip’s boisterous nightclub atmosphere and taking advantage of the consumption lounge to drive customer traffic to adjacent businesses. Cannabis tourism is a massive segment, says Christopher LaPorte, founder of marijuana hospitality firm Reset Vegas. LaPorte sees Las Vegas becoming a major marijuana tourism destination. Planet 13, a large entertainment center and dispensary near the Strip, is also looking to enter the consumption lounge segment by combining the lounge and restaurant experience.

It is steps like these in the development of the cannabis industry that show companies such as Prime Harvest Inc. that there is significant potential growth and opportunities in the industry if enabling laws and systems are put in place.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.